Advances in genomic techniques indicate that when TP53/CDKN2A genes are wild-type, as in testicular cancer, treatment with cytotoxic chemotherapy (e.g., cisplatin) produces complete responses that increase overall and disease-free survival57 (Fig. 2a, b). This evidence concerns the gene TP53 and testicular cancer.